SignaBlok to present novel approach to preventing cancer recurrence at the 2026 American Association for Cancer Research (AACR) annual meeting
SignaBlok to present favorable preclinical data on a first-in-class TREM-1 therapy for retinopathy of prematurity (ROP) at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting
SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop TREM-1 therapy for the treatment of empyema
SignaBlok, in collaboration with the University of Texas at Tyler, awarded NHLBI / NIH CATALYZE grant to develop a novel treatment for pleural infection (empyema)
SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of sepsis, pulmonary inflammation and fibrosis at the 2025 Respiratory Innovation Summit (RIS) and American Thoracic Society (ATS) International Conference
SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
SignaBlok presented preclinical data on the use of ligand-independent TREM-1 blockers as innate immune checkpoint inhibitors to overcome cancer immunotherapy resistance at the CICON23
SignaBlok awarded NEI / NIH SBIR Fast-Track grant to develop first-in-class TREM-1 inhibitors for neovascular retinal diseases
SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new mechanism-based TREM-1 therapy for acute respiratory distress syndrome
